Article Sidebar
Main Article Content
Assessment of Serum Dynamic Thiol/Disulfide Homeostasis and Oxidative/Nitrosative Stress in Patients with Crohn’s Disease
Main Article Content
Abstract
Background/Aims: Crohn’s disease (CD) is a major subtype of chronic relapsing inflammatory gastrointestinal disorders. In this study, we assessed the possible contributions of serum oxidative/nitrosative stress and dynamic thiol/disulfide homeostasis to CD pathogenesis.
Materials and Methods: Patients with active CD (A-CD) at onset (n = 38), CD patients in the remission (R-CD) (n = 38), and healthy controls (n = 38) were prospectively included in this study. Serum oxidative/nitrosative parameters as well as total thiol and native thiol levels were analyzed.
Results: We observed significant augmentation in nitric oxide (NO) levels in both A-CD and R-CD patients compared to healthy controls. We detected marked reductions in the 3-nitrotyrosine levels in the patient groups. Glutathione, glutathione peroxidase, and myeloperoxidase levels were observed to be significantly lower in both the active and remission groups (P < .001). In the A-CD group, native thiol (P < .001) and total thiol (P < .01) levels were lower, and disulfide levels were higher than those of the control group (P < .01), while the native thiol/total thiol ratio was reduced and disulfide/total thiol (P < .001) and disulfide/native thiol (P < .001) ratios were elevated. Remarkably, no change in dynamic thiol/disulfide homeostasis was found in the R-CD group.
Conclusion: Our results showed increased serum NO levels and decreased antioxidant enzymes, particularly during the active phase of CD. Determination of thiol/disulfide homeostasis could help differentiate between the active and remission phases of the disease. Thiol/ disulfide parameters can be used as biomarkers for A-CD.
Cite this article as: Aysun Bağdaş A, Barutçu S, Saracaloğlu A, Demiryürek AT. Assessment of serum dynamic thiol/disulfide homeostasis and oxidative/nitrosative stress in patients with Crohn’s disease. Turk J Gastroenterol. 2025;36(2):114-123.
Article Details
References
1. Alemany-Cosme E, Sáez-González E, Moret I, et al. Oxidative stress in the pathogenesis of Crohn’s disease and the interconnection with immunological response, microbiota, external environmental factors, and epigenetics. Antioxidants (Basel). 2021;10(1):64. [CrossRef]
2. Törüner M, Ünal NG. Epigenetics of inflammatory bowel diseases. Turk J Gastroenterol. 2023;34(5):437-448. [CrossRef]
3. Kayar Y, Dertli R, Konür Ş, et al. Mucocutaneous manifestations and associated factors in patients with Crohn’s disease. Turk J Gastroenterol. 2022;33(11):945-954. [CrossRef]
4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. [CrossRef]
5. Guan G, Lan S. Implications of antioxidant systems in inflammatory bowel disease. BioMed Res Int. 2018;2018:1290179. [CrossRef]
6. Bourgonje AR, Gabriëls RY, de Borst MH, et al. Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease. Antioxidants (Basel). 2019;8(9):351. [CrossRef]
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-19. [CrossRef]
8. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8167):514. [CrossRef]
9. Yücel EM, Konduk BT, Saracaloglu A, et al. Investigation of dynamic thiol/disulfide homeostasis and nitrosative stress in patients with Wilson disease. Turk J Gastroenterol. 2021;32(9):765-773. [CrossRef]
10. Li L, Xu P, Zhang Z, Zhou X, Chen C, Lu C. Platelets can reflect the severity of Crohn’s disease without the effect of anemia. Clinics (Sao Paulo). 2020;75:e1596. [CrossRef]
11. Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn’s disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53(8):2208-2214. [CrossRef]
12. Oudkerk Pool M, Bouma G, Visser JJ, et al. Serum nitrate levels in ulcerative colitis and Crohn’s disease. Scand J Gastroenterol. 1995;30(8):784-788. [CrossRef]
13. Soufli I, Hablal A, Bessaad S, et al. Nitric oxide, neutrophil/lymphocyte, and platelet/lymphocyte ratios as promising inflammatory biomarkers in complicated Crohn’s disease: outcomes of corticosteroids and Anti-TNF-α therapies. Inflammation. 2023;46(3):1091-1105. [CrossRef]
14. Dijkstra G, Moshage H, van Dullemen HM, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol. 1998;186(4):416-421. [CrossRef]
15. Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B. Antioxidant and immune status in active Crohn’s disease. A possible relationship. Clin Nutr. 2000;19(1):43-48. [CrossRef]
16. Tüzün A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002;35(7):569-572. [CrossRef]
17. Verspaget HW, Peña AS, Weterman IT, Lamers CB. Diminished neutrophil function in Crohn’s disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut. 1988;29(2):223-228. [CrossRef]
18. Kruidenier L, Kuiper I, van Duijn W, et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol. 2003;201(1):7-16. [CrossRef]
19. Tavassolifar MJ, Changaei M, Salehi Z, et al. Redox imbalance in Crohn’s disease patients is modulated by azathioprine. Redox Rep. 2021;26(1):80-84. [CrossRef]
20. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, Akcay T. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci. 2007;52(7):1636-1641. [CrossRef]
21. Barros SÉL, Dias TMDS, Moura MSB, et al. Relationship between selenium status and biomarkers of oxidative stress in Crohn’s disease. Nutrition. 2020;74:110762. [CrossRef]
22. Iantomasi T, Marraccini P, Favilli F, Vincenzini MT, Ferretti P, Tonelli F. Glutathione metabolism in Crohn’s disease. Biochem Med Metab Biol. 1994;53(2):87-91. [CrossRef]
23. Szczeklik K, Krzyściak W, Cibor D, et al. Evaluation of plasma concentrations of selected antioxidant parameters in patients with active Crohn’s disease. Folia Med Cracov. 2018;58(2):119-130. [CrossRef]
24. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Dröge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998;42(4):485-492. [CrossRef]
25. Abbas ZK, Zaidan TF. Oral findings, oxidative stress and antioxidant biomarker assessment in serum and saliva of Crohn’s patients. Int J Sci Res. 2017;6:1684-1687.
26. Ruan EA, Rao S, Burdick JS, et al. Glutathione levels in chronic inflammatory disorders of the human colon. Nutr Res. 1997;17(3):463-473. [CrossRef]
27. Passos RA, Costa PRF, da Maia Lima CF, et al. Thiols as a marker of inflammatory bowel disease activity: a systematic review. BMC Gastroenterol. 2023;23(1):94. [CrossRef]
28. Yuksel M, Ates I, Kaplan M, et al. The dynamic thiol/disulphide homeostasis in inflammatory bowel disease and its relation with disease activity and pathogenesis. Int J Colorectal Dis. 2016;31(6):1229-1231. [CrossRef]
29. Swaminathan A, Borichevsky GM, Edwards TS, et al. Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease. J Crohns Colitis. 2022;16(12):1862-1873. [CrossRef]
30. Chen Y, Wang Y, Shen J. Role of environmental factors in the pathogenesis of Crohn’s disease: a critical review. Int J Colorectal Dis. 2019;34(12):2023-2034. [CrossRef]